Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15168859 | 0.81 | — | — | |
| SCHEMBL26106213 | 0.81 | KAT2B (0.32) | — | |
| SCHEMBL31423181 | 0.79 | HTR7 (0.30) | — | |
| SCHEMBL19554677 | 0.77 | LMNA (0.34) | ALDH1A1LMNAMEN1KMT2AGAA | |
| SCHEMBL8305000 | 0.77 | KEAP1 (0.41) | KMT2A | |
| SCHEMBL1685272 | 0.75 | LIPG (0.38) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL2566044 | 0.75 | LIPG (0.38) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL8075810 | 0.75 | CYP2A6 (0.32) | — | |
| SCHEMBL320882 | 0.75 | LIPG (0.38) | ALDH1A1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL6047203 | 0.74 | PTGS2 (0.38) | ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435100-B2 | Perovskite solar cells | PURDUE RESEARCH FOUNDATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-11800784-B2 | Two-dimensional halide perovskite materials | PURDUE RESEARCH FOUNDATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-20220246865-A1 | PEROVSKITE SOLAR CELLS | PURDUE RESEARCH FOUNDATION (US) | 2022-08-04 | — | — | US | disclosed |
| US-20210343948-A1 | Two-Dimensional Halide Perovskite Materials | PURDUE RESEARCH FOUNDATION (US) | 2021-11-04 | — | — | US | disclosed |
| US-10618889-B2 | Thiophene monoamine based organic-inorganic hybrid perovskites | PURDUE RESEARCH FOUNDATION (US) | 2020-04-14 | — | — | US | disclosed |
| US-20200062740-A1 | THIOPHENE MONOAMINE BASED ORGANIC-INORGANIC HYBRID PEROVSKITES | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
| US-7144913-B2 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | MERCK FROSST CANADA & CO. (CA) | 2006-12-05 | — | — | US | disclosed |
| EP-1395590-B1 | DIHYDROPYRROLO¬1,2-A|INDOLE AND TETRAHYDROPYRIDO¬1,2-A|INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA INC (CA) | 2006-09-27 | — | — | EP | disclosed |
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | MERCK FROSST CANADA LTD. (CA) | 2004-09-16 | — | — | US | disclosed |
| EP-1395590-A2 | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-A]INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Merck Frosst Canada & Co. (CA) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094830-A2 | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA & CO. (CA) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618889-B2 | Thiophene monoamine based organic-inorganic hybrid perovskites | COMT, TYR, SLC6A3 | ALDH1A1 751/4885LMNA 4797/4885MEN1 1578/4885 |
| US-20210343948-A1 | Two-Dimensional Halide Perovskite Materials | EYA2, BRAP, EYA3 | ALDH1A1 2678/4885LMNA 2838/4885MEN1 1450/4885 |
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | PTGDR, PTGDR2, PTGIR | ALDH1A1 860/4885LMNA 4685/4885MEN1 3859/4885 |
| US-20220246865-A1 | PEROVSKITE SOLAR CELLS | BCL3, MCL1, ANXA3 | ALDH1A1 2526/4885LMNA 1735/4885MEN1 390/4885 |
| US-12435100-B2 | Perovskite solar cells | BCL3, MCL1, ANXA3 | ALDH1A1 2526/4885LMNA 1735/4885MEN1 390/4885 |
| US-11800784-B2 | Two-dimensional halide perovskite materials | EYA2, BRAP, EYA3 | ALDH1A1 2678/4885LMNA 2838/4885MEN1 1450/4885 |
| US-20200062740-A1 | THIOPHENE MONOAMINE BASED ORGANIC-INORGANIC HYBRID PEROVSKITES | COMT, TYR, SLC6A3 | ALDH1A1 751/4885LMNA 4797/4885MEN1 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.